Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.

MLA

O’Halloran, Jane A., et al. “Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.” JAMA, vol. 330, no. 4, July 2023, pp. 328–39. EBSCOhost, https://doi.org/10.1001/jama.2023.11043.

APA

O’Halloran, J. A., Ko, E. R., Anstrom, K. J., Kedar, E., McCarthy, M. W., Panettieri, R. A., Jr, Maillo, M., Nunez, P. S., Lachiewicz, A. M., Gonzalez, C., Smith, P. B., de Tai, S. M.-T., Khan, A., Lora, A. J. M., Salathe, M., Capo, G., Gonzalez, D. R., Patterson, T. F., Palma, C., … Powderly, W. G. (2023). Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA, 330(4), 328–339. https://doi.org/10.1001/jama.2023.11043

Chicago

O’Halloran, Jane A, Emily R Ko, Kevin J Anstrom, Eyal Kedar, Matthew W McCarthy, Reynold A Panettieri Jr, Martin Maillo, et al. 2023. “Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.” JAMA 330 (4): 328–39. doi:10.1001/jama.2023.11043.